Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 4
2007 4
2008 2
2009 1
2010 3
2011 5
2012 5
2013 4
2014 2
2015 6
2016 4
2017 5
2018 8
2019 4
2020 5
2021 6
2022 5
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
Mastini C, Campisi M, Patrucco E, Mura G, Ferreira A, Costa C, Ambrogio C, Germena G, Martinengo C, Peola S, Mota I, Vissio E, Molinaro L, Arigoni M, Olivero M, Calogero R, Prokoph N, Tabbò F, Shoji B, Brugieres L, Geoerger B, Turner SD, Cuesta-Mateos C, D'Aliberti D, Mologni L, Piazza R, Gambacorti-Passerini C, Inghirami GG, Chiono V, Kamm RD, Hirsch E, Koch R, Weinstock DM, Aster JC, Voena C, Chiarle R. Mastini C, et al. Among authors: mologni l. Sci Transl Med. 2023 Jun 28;15(702):eabo3826. doi: 10.1126/scitranslmed.abo3826. Epub 2023 Jun 28. Sci Transl Med. 2023. PMID: 37379367
Dual Kinase Targeting in Leukemia.
Mologni L, Marzaro G, Redaelli S, Zambon A. Mologni L, et al. Cancers (Basel). 2021 Jan 1;13(1):119. doi: 10.3390/cancers13010119. Cancers (Basel). 2021. PMID: 33401428 Free PMC article. Review.
Novel targeted therapeutics for MEN2.
Redaelli S, Plaza-Menacho I, Mologni L. Redaelli S, et al. Among authors: mologni l. Endocr Relat Cancer. 2018 Feb;25(2):T53-T68. doi: 10.1530/ERC-17-0297. Endocr Relat Cancer. 2018. PMID: 29348306 Review.
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Crespiatico I, Zaghi M, Mastini C, D'Aliberti D, Mauri M, Mercado CM, Fontana D, Spinelli S, Crippa V, Inzoli E, Manghisi B, Civettini I, Ramazzotti D, Sangiorgio V, Gengotti M, Brambilla V, Aroldi A, Banfi F, Barone C, Orsenigo R, Riera L, Riminucci M, Corsi A, Breccia M, Morotti A, Cilloni D, Roccaro A, Sacco A, Stagno F, Serafini M, Mottadelli F, Cazzaniga G, Pagni F, Chiarle R, Azzoni E, Sessa A, Gambacorti-Passerini C, Elli EM, Mologni L, Piazza R. Crespiatico I, et al. Among authors: mologni l. Blood. 2024 Apr 4;143(14):1399-1413. doi: 10.1182/blood.2023021349. Blood. 2024. PMID: 38194688
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo.
Massimino L, Palmieri O, Facoetti A, Fuggetta D, Spanò S, Lamparelli LA, D'Alessio S, Cagliani S, Furfaro F, D'Amico F, Zilli A, Fiorino G, Parigi TL, Noviello D, Latiano A, Bossa F, Latiano T, Pirola A, Mologni L, Piazza RG, Abbati D, Perri F, Bonini C, Peyrin-Biroulet L, Malesci A, Jairath V, Danese S, Ungaro F. Massimino L, et al. Among authors: mologni l. Gut. 2023 Oct;72(10):1838-1847. doi: 10.1136/gutjnl-2022-328375. Epub 2023 Feb 14. Gut. 2023. PMID: 36788014 Free PMC article.
We shall overcome (drug resistance) some day.
Sharma GG, Mologni L. Sharma GG, et al. Among authors: mologni l. Oncotarget. 2019 Jan 4;10(2):84-85. doi: 10.18632/oncotarget.26550. eCollection 2019 Jan 4. Oncotarget. 2019. PMID: 30719203 Free PMC article. No abstract available.
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A, Mauri M, Ramazzotti D, Villa M, Malighetti F, Crippa V, Cocito F, Borella C, Bossi E, Steidl C, Scollo C, Voena C, Chiarle R, Mologni L, Piazza R, Gambacorti-Passerini C. Aroldi A, et al. Among authors: mologni l. J Cell Mol Med. 2023 Oct;27(20):3053-3064. doi: 10.1111/jcmm.17868. Epub 2023 Aug 31. J Cell Mol Med. 2023. PMID: 37654003 Free PMC article.
Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition.
Zaghi M, Banfi F, Massimino L, Volpin M, Bellini E, Brusco S, Merelli I, Barone C, Bruni M, Bossini L, Lamparelli LA, Pintado L, D'Aliberti D, Spinelli S, Mologni L, Colasante G, Ungaro F, Cioni JM, Azzoni E, Piazza R, Montini E, Broccoli V, Sessa A. Zaghi M, et al. Among authors: mologni l. Nat Commun. 2023 Jun 3;14(1):3212. doi: 10.1038/s41467-023-39043-x. Nat Commun. 2023. PMID: 37270547 Free PMC article.
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
Karaca Atabay E, Mecca C, Wang Q, Ambrogio C, Mota I, Prokoph N, Mura G, Martinengo C, Patrucco E, Leonardi G, Hossa J, Pich A, Mologni L, Gambacorti-Passerini C, Brugières L, Geoerger B, Turner SD, Voena C, Cheong TC, Chiarle R. Karaca Atabay E, et al. Among authors: mologni l. Blood. 2022 Feb 3;139(5):717-731. doi: 10.1182/blood.2020008136. Blood. 2022. PMID: 34657149 Free PMC article.
80 results